Thesis (Master's)--University of Washington, 2015-12In clinical trials, the comparison of binary outcomes between two independent treatment groups is most commonly measured by either relative or absolute differences between outcome rates. In the setting of a non-inferiority (NI) trial, an NI margin corresponding to one of these measures is defined to represent the maximum clinically meaningful limit by which an experimental intervention will be considered allowably inferior to a standard-of-care (SOC) treatment regimen. In the instance of extreme event rates, special consideration should be given to the intervention's allowable outcome rates as defined by the SOC rate and the NI margin in order to produce a meaningful assessment of the inte...
Abstract Background There are significant challenges to the successful conduct of non-inferiority tr...
Protocol non-adherence is common and poses unique challenges in the interpretation of trial outcomes...
Protocol non-adherence is common and poses unique challenges in the interpretation of trial outcomes...
When a new treatment is compared to an established one in a randomized clinical trial, it is standar...
Superiority trials are conducted to test the hypothesis that a treatment or strategy A is superior t...
Clinical trials are an essential part of the drug development life cycle. There are different types ...
Superiority trials are conducted to test the hypothesis that a treatment or strategy A is superior t...
Clinical trials are an essential part of the drug development life cycle. There are different types ...
Superiority trials are conducted to test the hypothesis that a treatment or strategy A is superior t...
Superiority trials are conducted to test the hypothesis that a treatment or strategy A is superior t...
Superiority trials are conducted to test the hypothesis that a treatment or strategy A is superior t...
Choosing the equivalence margin for a non-inferiority trial of an anti-infective medication involves...
Despite decades of experience with non-inferiority trials, they remain a source of great controversy...
Non-inferiority (NI) clinical trials are widely used to evaluate whether the new experimental treatm...
Contains fulltext : 57330.pdf (publisher's version ) (Closed access)In clinical tr...
Abstract Background There are significant challenges to the successful conduct of non-inferiority tr...
Protocol non-adherence is common and poses unique challenges in the interpretation of trial outcomes...
Protocol non-adherence is common and poses unique challenges in the interpretation of trial outcomes...
When a new treatment is compared to an established one in a randomized clinical trial, it is standar...
Superiority trials are conducted to test the hypothesis that a treatment or strategy A is superior t...
Clinical trials are an essential part of the drug development life cycle. There are different types ...
Superiority trials are conducted to test the hypothesis that a treatment or strategy A is superior t...
Clinical trials are an essential part of the drug development life cycle. There are different types ...
Superiority trials are conducted to test the hypothesis that a treatment or strategy A is superior t...
Superiority trials are conducted to test the hypothesis that a treatment or strategy A is superior t...
Superiority trials are conducted to test the hypothesis that a treatment or strategy A is superior t...
Choosing the equivalence margin for a non-inferiority trial of an anti-infective medication involves...
Despite decades of experience with non-inferiority trials, they remain a source of great controversy...
Non-inferiority (NI) clinical trials are widely used to evaluate whether the new experimental treatm...
Contains fulltext : 57330.pdf (publisher's version ) (Closed access)In clinical tr...
Abstract Background There are significant challenges to the successful conduct of non-inferiority tr...
Protocol non-adherence is common and poses unique challenges in the interpretation of trial outcomes...
Protocol non-adherence is common and poses unique challenges in the interpretation of trial outcomes...